TRGNF - Transgene teams up with NEC and BostonGene for ovarian and head & neck cancer studies

Transgene ([[TRGNF]]), NEC Corp ([[NIPNF]]) and BostonGene have announced a strategic collaboration for two Phase 1 trials of TG4050, an individualized therapeutic vaccine for ovarian and head & neck cancers.TG4050 is based on Transgene’s proprietary myvac platform and NEC’s AI-driven Neoantigen Prediction System, and aims stimulating the immune system of patients to induce a T-cell response against tumor-specific antigenic alterations, called neoantigens. TG4050 has been designed to target up to 30 patient-specific neoantigens.As part of the collaboration, BostonGene will conduct genomic and transcriptomic analyses of primary patient tumors to identify predictors of response to TG4050 and the cancer cell-intrinsic and -extrinsic factors that may mediate each patient’s response to the vaccine. BostonGene’s platform integrates the genomic and transcriptomic analyses to simultaneously assess the activity of the tumor.

For further details see:

Transgene teams up with NEC and BostonGene for ovarian and head & neck cancer studies